Novel biomarker shows promise as predictor of post-hepatectomy outcomes in HCC

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.

Key clinical point: A novel biomarker incorporating albumin, lymphocytes, and C-reactive protein levels, known as the CALLY index, was a significant independent predictor of 5-year survival in HCC patients who underwent hepatectomy.

Major finding: In a multivariate analysis, 5-year survival was significantly higher in patients with a CALLY index of 5 or higher than in those with a CALLY index less than 5 (73% vs 48%).

Study details: The data come from 384 adults with HCC who underwent hepatectomy at four hospitals in Japan between January 2011 and December 2013. Researchers compared outcomes for 200 patients with a CALLY index of 5 or higher to 184 patients with an index less than 5. The index was validated using an external cohort of 267 patients from three additional hospitals.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Iida H et al. HPB (Oxford). 2021 Jun 22. doi: 10.1016/j.hpb.2021.06.414.